A new HOPE for aldosterone blockade?

Circulation

Volumn 110, Issue 13, 2004, Pages 1714-1716

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Aldosterone; Angiotensin; Coronary disease; Editorials

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CORONARY BLOOD VESSEL; DRUG EFFICACY; EDITORIAL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROKE; SUDDEN DEATH;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; ANIMALS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FIBROBLASTS; HUMANS; LIPOPROTEINS, LDL; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, CARDIAC; NITRIC OXIDE; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, LDL; RECEPTORS, MINERALOCORTICOID; RECEPTORS, OXIDIZED LDL; RECOMBINANT FUSION PROTEINS; RENIN; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION;

EID: 4644328671     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000144399.60132.3D     Document Type: Editorial

References (21)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 2003;341:709-717.
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
3. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillipis RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy Study. Circulation. 2003;108:1831-1838.
4. Hatakeyama H, Miyamori I, Takeda Y, Yamamoto H, Mabuchi H. The expression of steroidogenic enzyme genes in human vascular cells. Biochem Mol Biol Int. 1996;40:639-645.
5. Okubo S, Niimura F, Nishimura H, Takemoto F, Fogo A, Matsusaka T, Ichikawa I. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellcular fluid volume depletion. J Clin Invest. 1997;99:855-860.
6. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
7. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet. 2003;362:782-788.
8. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorficoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105:2212-2216.
9. Mitchell BM, Smith AD, Webb RC, Dorrance AM. Aldosterone decreases endothelium-dependent relaxation by down-regulating GTP cyclohydrolase. Hypertension. 2003;42:435(P161). Abstract.
10. Luft FC. Mechanisms and cardiovascular damage in hypertension. Hypertension. 2001;37:594-598.
11. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
12. Kobayashi N, Honda T, Hara K, Mita S, Nakano S, Yoshida K, Tsubokou Y, Ono H, Matsuoka H. Hypertension. 2003;42:446(P216). Abstract.
13. Szmitko PE, Wang C-H, Weisel RD, Jeffries GA, Anderson TJ, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation, part II. Circulation. 2003;108:2041-2048.
14. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T, Nakamura S, Kuwahara K, Saito Y, Nakao K, Ogawa H. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation. 2001;104:137-139.
15. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension. 1992;20:67-73.
16. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin- converting enzyme and the receptors for angiotensin I and aldosterone. Circulation. 2004;109:2213-2220.
17. Michel F, Ambroisine M-L, Duriez M, Delcayre C, Levy BI, Silvestre J-S. Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation. 2004;109:1933-1937.
18. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EAG, NcMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol. 2002;283:H1802-H1810.
19. Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 2002;106:2967-2972.
20. Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochias F, Hoerter J, Nehme J, Ambroisine ML, DeAngelis N, Morineau G, d'Estienne P, Fischmeister R, Heymes C, Pinet F, Delcayre C. Cardiac-specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation. 2004;110:1819-1825.
21. Mazak I, Fiebeler A, Muller DN, Park J-K, Shangdarsuren E, Linschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109:2792-2800.